ZYME Stock Zymeworks (ZYME, $14.91) Moving Average Convergence Divergence (MACD) Histogram turned positive on February 6, 2025

GET DAILY SIGNALS

Get AI intraday signals

ZYME - Zymeworks

MACD signal

View

Odds of UP Trend

Price: $14.91

Daily change: +$0.67 (+4.71%)

Daily volume: 225.1K

Capitalization: $1B

Industry: Biotechnology

ZYME in upward trend: price expected to rise as it breaks its lower Bollinger Band on February 11, 2025

ZYME may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 41 cases where ZYME's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for ZYME just turned positive on February 14, 2025. Looking at past instances where ZYME's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

ZYME moved above its 50-day moving average on February 12, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ZYME crossed bullishly above the 50-day moving average on January 28, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZYME advanced for three days, in of 295 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 210 cases where ZYME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Momentum Indicator moved below the 0 level on February 18, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ZYME as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZYME declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ZYME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.703) is normal, around the industry mean (12.604). P/E Ratio (0.000) is within average values for comparable stocks, (85.387). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.581). ZYME has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (17.331) is also within normal values, averaging (252.111).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZYME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.